Synthetic Biologics, Inc.

277 articles about Synthetic Biologics, Inc.

• Synthetic Biologics Reports First Quarter 2019 Operational Highlights and Financial Results

  5/8/2019

  Enrollment is Ongoing in Phase 2b Investigator-Sponsored Clinical Study of SYN-010, for the Treatment of IBS-C; Topline Data Readout Anticipated in 2H 2019

• Synthetic Biologics Reports 2018 Year End Operational Highlights and Financial Results

  2/27/2019

  Enrollment is Ongoing in Phase 2b Investigator-Sponsored Clinical Study of SYN-010, for the Treatment of IBS-C; Topline Data Readout Anticipated in 2H 2019

• Synthetic Biologics to Report 2018 Year End Operational Highlights and Financial Results on February 27, 2019

  2/19/2019

  Synthetic Biologics, Inc., a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, intends to report operational highlights and financial results for the year ended December 31, 2018 on Wednesday, February 27, 2019, and will host a conference call the same day at 4:30 p.m. EST.

• 

  Synthetic Biologics' Drug to Prevent C. Diff Infections Gets Phase III Go-Ahead from FDA

  11/21/2018

  The company and the agency discussed the development of SYN-004 (ribaxamase) to prevent antibiotic-mediated Clostridium difficile infection (CDI).

• Synthetic Biologics Reports Third Quarter 2017 Operational Highlights and Financial Results

  11/2/2017

  Synthetic Biologics today provided an operational update and reported financial results for the three months ended September 30, 2017.

• Synthetic Biologics to Report Third Quarter 2017 Operational Highlights and Financial Results on November 1, 2017

  10/25/2017

  Synthetic Biologics announced today that the Company intends to release its operational highlights and financial results for the quarter ended September 30, 2017 on Wednesday, November 1, 2017, and to host a conference call the same day at 4:30 p.m. EDT.

• Synthetic Biologics Announces Closing Of $12 Million Convertible Preferred Stock Financing

  9/12/2017

• Synthetic Biologics Reports Second Quarter 2017 Operational Highlights And Financial Results

  8/3/2017

• Synthetic Biologics To Report Second Quarter 2017 Operational Highlights And Financial Results On August 3, 2017

  7/27/2017

• Synthetic Biologics Announces Allowance Of Key U.S. Patent Covering SYN-010 Intended For The Novel Treatment Of Irritable Bowel Syndrome With Constipation (IBS-C)

  6/27/2017

• Synthetic Biologics Release: SYN-004 (Ribaxamase) Receives Breakthrough Therapy Designation From FDA For Prevention Of Clostridium Difficile Infection

  5/11/2017

• Synthetic Biologics Reports First Quarter 2017 Operational Highlights And Financial Results

  5/5/2017

• Synthetic Biologics To Report First Quarter 2017 Operational Highlights And Financial Results On May 4, 2017

  4/27/2017

• Synthetic Biologics Reports Preclinical Data Demonstrating SYN-005 Provides Protection From Pertussis In Neonatal Animal Study

  4/19/2017

• Synthetic Biologics Reports 2016 Year End Operational Highlights And Financial Results

  3/3/2017

• Synthetic Biologics To Report 2016 Year End Operational Highlights And Financial Results On March 2, 2017

  2/22/2017

• Synthetic Biologics Release: Company Confirms Key Features Of Pivotal Phase 2b/3 Trial Of SYN-010 Pursuant To Consultations With FDA

  1/19/2017

• Synthetic Biologics' SYN-004 (Ribaxamase) Achieves Primary Endpoint In Phase 2b Trial For C. Difficile Infection (CDI)

  1/5/2017

• Synthetic Biologics Announces Granting Of U.S. Composition Of Matter Patent For SYN-005, Designed For The Treatment And Prevention Of Pertussis (Whooping Cough)

  12/13/2016

• Synthetic Biologics Announces Closing Of Public Offering Of Common Stock And Warrants

  11/21/2016